X0206 3 2021-10-15 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001886575 Betz Stephen F. C/O CRINETICS PHARMACEUTICALS, INC. 10222 BARNES CANYON ROAD, BLDG 2 SAN DIEGO CA 92121 0 1 0 0 Chief Scientific Officer Common Stock 187925 D Stock Option (right to buy) 1.91 2028-03-16 Common Stock 182370 D Stock Option (right to buy) 9.28 2028-05-24 Common Stock 91185 D Stock Option (right to buy) 25.19 2029-03-07 Common Stock 56250 D Stock Option (right to buy) 22.61 2030-02-23 Common Stock 60000 D Stock Option (right to buy) 15.29 2031-02-25 Common Stock 85000 D Stock Option (right to buy) 23.19 2031-09-09 Common Stock 15000 D 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person. 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date; provided, however, that one-half of the shares subject to the option are subject to the further condition that they may not be exercised until the occurrence of the Issuer's initial public offering and, in the event the Issuer's initial public offering does not occur prior to the first anniversary of May 25, 2018, such portion of the stock options shall be automatically forfeited. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement Date of March 8, 2019. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of September 1, 2021. /s/ Marc Wilson, as attorney-in-fact 2021-10-18